These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 19669630)

  • 21. Evaluation of risk factors and health outcomes among persons with asthma.
    Smith K; Warholak T; Armstrong E; Leib M; Rehfeld R; Malone D
    J Asthma; 2009 Apr; 46(3):234-7. PubMed ID: 19373629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population.
    Davis KL; Candrilli SD; Edin HM
    Epilepsia; 2008 Mar; 49(3):446-54. PubMed ID: 18031549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of asthma exacerbation, asthma-related health care utilization and costs, and adherence to controller therapy in patients with asthma receiving fluticasone propionate/salmeterol inhalation powder 100 μg/50 μg versus mometasone furoate inhalation powder.
    Hagiwara M; Delea TE; Stanford RH
    J Asthma; 2013 Apr; 50(3):287-95. PubMed ID: 23305687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The small airway inflammation of asthmatic patients who have used dry powder type inhaled steroid for moderate-long term evaluated by induced sputum and the efficacy of HFA-BDP (QVAR) inhalation].
    Ohbayashi H
    Arerugi; 2005 Jan; 54(1):24-35. PubMed ID: 15841673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of patients treated with fluticasone propionate or montelukast sodium.
    Allen-Ramey FC; Duong PT; Goodman DC; Sajjan SG; Nelsen LM; Markson L
    Manag Care Interface; 2003 Aug; 16(8):30-5. PubMed ID: 12964550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stepping down from high dose fluticasone/salmeterol to extrafine BDP/F in asthma is cost-effective.
    Paggiaro P; Patel S; Nicolini G; Pradelli L; Zaniolo O; Papi A
    Respir Med; 2013 Oct; 107(10):1531-7. PubMed ID: 23916740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population.
    Ye X; Gutierrez B; Zarotsky V; Nelson M; Blanchette CM
    Curr Med Res Opin; 2009 Sep; 25(9):2251-8. PubMed ID: 19622006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing outcomes in patients with persistent asthma: a registry of two therapeutic alternatives.
    O'Connor RD; Gilmore AS; Manjunath R; Stanford RH; Legorreta AP; Jhingran PM
    Curr Med Res Opin; 2006 Mar; 22(3):453-61. PubMed ID: 16574029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 microg day(-1)) versus HFA-fluticasone propionate (1000 microg day(-1)) in patients with asthma.
    Aubier M; Wettenger R; Gans SJ
    Respir Med; 2001 Mar; 95(3):212-20. PubMed ID: 11266239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy and cost of asthma care in children with asthma treated with fluticasone propionate and montelukast.
    Stempel DA; Kruzikas DT; Manjunath R
    J Pediatr; 2007 Feb; 150(2):162-7. PubMed ID: 17236894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A multicenter, open-label, randomized comparison of suppressive effects on asthmatic inflammation of lower airways and improved effects on health-related QOL between HFA-BDP and fluticasone propionate].
    Ohbayashi H; Adachi M; Ichinose M; Ohta K; Kokubu F; Sano Y; Tamura G; Tohda Y; Hirata K; Yasuba H
    Arerugi; 2007 Jun; 56(6):577-86. PubMed ID: 17615501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-inflammatory medication adherence and cost and utilization of asthma care in a commercially insured population.
    Mattke S; Martorell F; Hong SY; Sharma P; Cuellar A; Lurie N
    J Asthma; 2010 Apr; 47(3):323-9. PubMed ID: 20394518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study.
    Faught RE; Weiner JR; Guérin A; Cunnington MC; Duh MS
    Epilepsia; 2009 Mar; 50(3):501-9. PubMed ID: 19183224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of prevalence, cost, and outcomes of a combination of salmeterol and fluticasone therapy to common asthma treatments.
    Wang SW; Liu X; Wiener DJ; Sennett C; Bowers BW; Legorreta AP
    Am J Manag Care; 2001 Sep; 7(9):913-22. PubMed ID: 11570024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone.
    Colice G; Martin RJ; Israel E; Roche N; Barnes N; Burden A; Polos P; Dorinsky P; Hillyer EV; Lee AJ; Chisholm A; von Ziegenweidt J; Barion F; Price D
    J Allergy Clin Immunol; 2013 Jul; 132(1):45-54. PubMed ID: 23591272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate.
    Fowler SJ; Orr LC; Wilson AM; Sims EJ; Lipworth BJ
    Br J Clin Pharmacol; 2001 Jul; 52(1):93-5. PubMed ID: 11453895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retrospective comparison of early versus late treatment with fluticasone propionate/salmeterol after an asthma exacerbation.
    Hagiwara M; Delea TE; Stanford RH
    J Asthma; 2011 Sep; 48(7):721-8. PubMed ID: 21793768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.